HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, March 14 (HealthDay News) -- The U.S. Food and Drug Administration has granted approval to a new anti-cancer treatment, Tykerb (lapatinib), for use in combination with Xeloda (capectabine) for treatment of patients with advanced metastatic HER2-positive breast cancer. Women who have already been treated with other cancer drugs such as an anthracycline, a taxane, or Herceptin (trastuzumab) can be prescribed the drug.
Tykerb is a small molecule kinase inhibitor that enters cells and curbs tumor cell growth internally rather than targeting proteins on the outside of the cell. Therefore, it may benefit women with HER2-positive breast cancer that is not responding to Herceptin or other therapies.
A clinical trial of 400 women generated sufficient results to allow the drug's approval, but data on survival rates are not yet available. Side-effects include diarrhea, nausea, vomiting, rash and hand-foot syndrome.
"Today's approval is a step forward in making new treatments available for patients who have progression of their breast cancer after treatment with some of the most effective breast cancer therapies available," said Steven Galston, M.D., M.P.H., director of the FDA's Center for Drug Evaluation and Research, in a statement. "New targeted therapies such as Tykerb are helping expand options for patients."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.